Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 25 Oct 2026
Promising but preliminary

RAS-Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer

Genetic sequencing identifies a treatable mutation in 3% of colorectal cancers, creating precision treatment opportunities for this subset of patients.

Whole-exome sequencing of 1,243 paired colorectal cancer samples from a multi-institutional NCI-funded cohort characterizes KRAS, NRAS, HRAS, BRAF, and PIK3CA mutations with co-occurrence patterns and ethnic-group comparisons. The 3.1% KRAS G12C prevalence defines a targetable precision oncology opportunity, while negative OS associations after adjustment suggest mutation status alone does not determine survival in this unselected population.

What the study was

Study design
Cohort study (whole-exome sequencing)
Category
T5: Precision oncology and genomic medicine
Maturity
Validated
Journal
Cancer Medicine

Why it surfaced

Large multi-ethnic NCI-funded WES dataset providing actionable KRAS G12C prevalence data for CRC precision oncology; co-mutation patterns and ethnic disparities in BRAF V600E are directly relevant to watchlist precision oncology and therapy-selection goals.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.